These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 30481756)
1. Management of Dopamine Agonist-Resistant Prolactinoma. Maiter D Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756 [TBL] [Abstract][Full Text] [Related]
2. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458 [TBL] [Abstract][Full Text] [Related]
3. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500 [TBL] [Abstract][Full Text] [Related]
4. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and drug therapy of prolactinoma. Ciccarelli E; Camanni F Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617 [TBL] [Abstract][Full Text] [Related]
6. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301 [TBL] [Abstract][Full Text] [Related]
7. Phenotype and resistance patterns of 10 resistant prolactinomas. Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099 [TBL] [Abstract][Full Text] [Related]
8. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma. Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887 [TBL] [Abstract][Full Text] [Related]
9. Dopamine resistance of prolactinomas. Molitch ME Pituitary; 2003; 6(1):19-27. PubMed ID: 14674720 [TBL] [Abstract][Full Text] [Related]
10. Resistant prolactinomas: a case series of 26 patients. Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631 [TBL] [Abstract][Full Text] [Related]
11. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type. Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178 [TBL] [Abstract][Full Text] [Related]
12. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478 [TBL] [Abstract][Full Text] [Related]
13. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas. Yarman S; Kurtulmus N; Bilge A Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Prolactinoma. Inder WJ; Jang C Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562 [TBL] [Abstract][Full Text] [Related]
15. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904 [TBL] [Abstract][Full Text] [Related]
16. Pharmacologic resistance in prolactinoma patients. Molitch ME Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068 [TBL] [Abstract][Full Text] [Related]
17. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment. Shimon I Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507 [TBL] [Abstract][Full Text] [Related]
18. Italian Guidelines for the Management of Prolactinomas. Cozzi R; Simona Auriemma R; De Menis E; Esposito F; Ferrante E; Iatì G; Mazzatenta D; Poggi M; Rudà R; Tortora F; Cruciani F; Mitrova Z; Saulle R; Vecchi S; Basile M; Cappabianca P; Paoletta A; Papini E; Persichetti A; Samperi I; Scoppola A; Bozzao A; Caputo M; Doglietto F; Ferraù F; Lania AG; Laureti S; Lello S; Locatelli D; Maffei P; Minniti G; Peri A; Ruini C; Settanni F; Silvani A; Veronese N; Grimaldi F; Attanasio R Endocr Metab Immune Disord Drug Targets; 2023; 23(12):1459-1479. PubMed ID: 37171003 [TBL] [Abstract][Full Text] [Related]